| abstract |
Compositions containing compounds, or pharmaceutically acceptable salts, which are metabolized in monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or improvement of neurodegenerative diseases including multiple sclerosis using such compositions in a subject are provided herein. where if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w / w to about 95% w / w. |